Selloff or Market Correction? Either Way, Here's What to Do NextSee Overvalued Stocks

Mailing abortion pills could break law, Republican AGs tell pharmacies

Published 02/01/2023, 07:19 PM
Updated 02/02/2023, 12:17 PM
© Reuters. FILE PHOTO: Used boxes of Mifepristone pills, the first drug used in a medical abortion, fill a trashcan at Alamo Women's Clinic in Albuquerque, New Mexico, U.S., January 11, 2023. REUTERS/Evleyn Hockstein
CVS
-
WBA
-

By Brendan Pierson

(Reuters) - A group of 20 Republican state attorneys general on Wednesday told Walgreens Boots Alliance (NASDAQ:WBA) Inc and CVS Health Corp (NYSE:CVS) that they risk running afoul of federal and state law if they dispense the abortion drug mifepristone by mail.

The move, announced by Missouri Attorney General Andrew Bailey, comes weeks after the U.S. Food and Drug Administration for the first time allowed retail pharmacies to dispense mifepristone, including by mail, provided they are certified under special safety rules for the drug.

Walgreens and CVS have said they intend to become certified and dispense the drug in states where abortion is legal, though neither has yet done so.

"We intend to become a certified pharmacy under the program, however we fully understand that we may not be able to dispense mifepristone in all locations if we are certified under the program," Walgreens spokesperson Fraser Engerman said in an email.

CVS did not immediately respond to a request for comment.

Medication abortion, which accounts for more than half of U.S. abortions, has drawn increasing attention since the U.S. Supreme Court last June overturned its landmark 1973 Roe v. Wade ruling that had recognized abortion as a constitutional right nationwide.

Mifepristone, used in combination with another drug, misoprostol, is approved for abortion within the first 10 weeks of pregnancy.

In their letters to the pharmacies Wednesday, the attorneys general said that the Comstock Act, a 19th century federal law, expressly prohibits using the mail to send or receive any drug that will “be used or applied for producing abortion.”

The Biden administration earlier this month said mailing mifepristone would not violate that law if the sender does not intend for it to be used unlawfully.

© Reuters. FILE PHOTO: Used boxes of Mifepristone pills, the first drug used in a medical abortion, fill a trashcan at Alamo Women's Clinic in Albuquerque, New Mexico, U.S., January 11, 2023. REUTERS/Evleyn Hockstein

The attorneys general called this interpretation "bizarre" and warned that mailing the drug could violate some states' laws.

Mifepristone is currently the subject of multiple lawsuits. Anti-abortion activists are asking a Texas judge to revoke its approval by the U.S. Food and Drug Administration, which would effectively pull it off the market. Meanwhile, generic mifepristone manufacturer GenBioPro and a doctor have challenged restrictions on the drug in West Virginia and North Carolina, respectively.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.